Wegovy pill 4 mg price steps up from $149 to $199

Novo Nordisk's promotional cash price for the 4 mg dose of the Wegovy pill has ended, pushing the self-pay cost from $149 to $199 a month as of April 15, 2026 ^[1]. The change affects only the second-lowest dose of the oral version of semaglutide. The 1.5 mg starter dose remains $149 a month, and the two higher doses, 9 mg and 25 mg, stay at $299 a month ^[1][2].

The Wegovy pill launched in January 2026 with a limited-time offer covering both the 1.5 mg and 4 mg doses at $149 through April 15, 2026, after which the $199 price for 4 mg would take effect, according to GoodRx, which distributes the manufacturer's cash pricing at more than 70,000 pharmacies nationwide ^[1]. Novo Nordisk's own NovoCare pricing page confirms the same tiered structure: $149 for 1.5 mg, $199 for 4 mg, and $299 for 9 mg and 25 mg for self-pay patients ^[2].

These cash prices apply to people paying out of pocket without insurance coverage. Separately, patients with commercial insurance may pay as little as $25 a month through a savings program, subject to a maximum savings of $100 a month, with government beneficiaries excluded from that offer ^[2]. The cash prices described here are distinct from the injectable Wegovy pen, which has its own separate self-pay pricing structure that is also time-limited under current offers ^[2].

Why it matters for patients

For people who started the Wegovy pill at the 4 mg dose during the introductory period, this is a real increase in monthly out-of-pocket cost if they are paying cash rather than using insurance or a manufacturer savings card. A $50 jump on a medication many people take long-term can add up over months of treatment. Patients who have not yet titrated up from the 1.5 mg starter dose are not affected by this particular change, since that price holds at $149 ^[1][2].

The pricing difference between doses also matters for anyone comparing the oral pill to the traditional Wegovy pen or to other GLP-1 options. Because the cash price structure is tiered by dose rather than flat, a patient's total monthly cost can shift as their prescribed dose increases during treatment, independent of any changes to insurance coverage. Neither source in this reporting specifies why the promotional period was set to expire on this particular date or whether further price changes are planned for other doses ^[1][2].

It is not yet known from these sources whether insurers or pharmacy benefit managers have adjusted their own coverage terms for the 4 mg dose in response to this price change, or how many patients are currently prescribed 4 mg versus other doses of the pill.

What happens next

The next scheduled pricing change noted in company materials involves the Wegovy pen rather than the pill: a separate limited-time offer for new patients on lower pen doses is set to run through December 31, 2026, after which pricing for those pen doses is set to increase to $349 or $399 a month depending on dose ^[2]. No additional expiration dates for the pill's cash pricing tiers are specified in the sources reviewed here.